Accelerating API development for first-in-human clinical studies

Moving a drug candidate from small molecule selection to first-in-human (FIH) clinical studies requires strategic API development. A well-defined development strategy can help shorten project timelines. As drug candidates grow more complex and pressure to reach clinical entry increases, API quantity, quality, and supply requirements must be established early.

Accelerating API development for first-in-human clinical studies

This webinar explores the best practices for building a reliable supply route. Topics include the optimization of synthetic processes and choosing suitable regulatory starting materials to support efficient good manufacturing practice (GMP)-compliant production. It also examines the roles of solid forms and materials science in API development, covering polymorph and salt screening, solid-form selection and stability assessment, and crystallization development, with a focus on robust form control and reproducibility. These considerations directly affect downstream formulation and manufacturability, making them essential to delivering high-quality APIs for FIH studies.

What will the webinar cover?

  • API material supply: The webinar will discuss how API material availability becomes a rate-limiting factor for downstream activities. We'll also explore the importance of incorporating appropriate sourcing strategies into development campaigns.
  • Regulatory starting materials and GMP production: We’ll examine how early decisions around regulatory starting materials and the route to GMP production influence CMC resource requirements, batch strategy, and logistics.
  • API solid form selection: We’ll look at the importance of solid form screening and the key physical properties to consider, including stability, solubility, and particle size. We’ll also discuss how these characteristics affect drug substance manufacturing and testing, as well as considerations for the final drug product.
  • Impurity coverage and analytical strategies: The webinar will discuss the importance of early planning for impurity coverage in development, including how this aids the selection of suitable analytical methods, supports phase-appropriate specifications, minimizes risk, and develops a foundation for drug substance testing and release.
  • The evolving regulatory landscape: We’ll review changing regulatory expectations surrounding non-mutagenic impurities, PMIs, and nitrosamines, and discuss how understanding these requirements can help build a robust, compliant data package to support clinical progression.

Other Webinars from Pharmaron – End-to-End CRO/CDMO

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.